Asia Pacific

Haitong UniTrust International Leasing Corp has finally begun bookbuilding for an IPO, more than two years after it first announced plans to list on the Hong Kong Stock Exchange.

Chinese issuer Huachen Energy has skipped a dollar bond coupon, as its troubled parent company Wintime Energy slips further into a liquidity crisis.

JP Morgan’s private equity arm has bagged W390.7bn ($327.5m) after selling a chunk of shares in South Korean firm Celltrion Healthcare, according to a source close to the deal.

Xinyi Energy Holdings has come through tough market conditions to finalise its Hong Kong IPO, pricing the deal towards the bottom of the guidance range.

South Korean company SK Biopharmaceuticals is planning to launch an IPO by the end of 2019 and could net proceeds of up to around W1tr ($838.5m), according to a source close to the deal.

Oceanwide Holdings Co has priced a new $280m two year bond to replace in part an imminent maturity, paying one of the highest yields Asia has seen so far this year.

China Lesso Group Holdings, a manufacturer of home building materials, is preparing to refinance two loans with 2020 maturities, inviting existing lenders to join the mandated lead arranger and bookrunner group.

Hansoh Pharmaceutical Group has won approval from the Hong Kong Stock Exchange for a new listing worth up to $1bn.

Liu Shiyu, former chairman of the China Securities and Regulatory Commission (CSRC), is under investigation after turning himself in to the nation’s corruption watchdog, according to a statement on Sunday.

MSCI has poached Tay Kim from Franklin Templeton Investment Trust Management to lead client coverage for the firm in South Korea.

Neville Fernandes has left his position as the head of debt capital markets for India at Citi.

Biopharmaceutical company Mabpharm has launched the deal roadshow for its IPO and is targeting proceeds of up to HK$1.53bn ($194.7m).